From the above docking report, we find that along with Remdesivir , a drug already being tested for its effectiveness against COVID-19, cloperastine and vigabatrin show promise as possible candidates for treating COVID-19. Cloperastine is a cough suppressant that acts on the central nervous system and vigabatrin is a medication used to treat epilepsy. These drugs perform better than the baseline N3 ligand which had an affinity of 7.9kcal/mol.